March 6 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:
ENTERING INTO AN EXCLUSIVE COOPERATION AGREEMENT WITH DELOVA BIOTECH FOR QP001
EXPECTS THAT PRODUCT WILL BE APPROVED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA FOR MARKETING IN NEAR FUTURE
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.